Affordable Access

Effect of whole-body hyperthermia on pharmacokinetics and tissue distribution of doxorubicin.

Authors
  • Newman, R A
  • Dogramatzis, D
  • Benvenuto, J A
  • Trevino, M
  • Stephens, L C
  • Wondergem, J
  • Strebel, R
  • Baba, H
  • Bull, J M
Type
Published Article
Journal
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
Publication Date
Jan 01, 1992
Volume
8
Issue
1
Pages
79–85
Identifiers
PMID: 1545165
Source
Medline
License
Unknown

Abstract

The effect of whole-body hyperthermia (41.5 degrees C, 2 h) on doxorubicin (DOX) tissue distribution and plasma pharmacokinetics was examined in rats bearing a subcutaneous fibrosarcoma. Tumour response to the hyperthermia regimen alone was minimal, but the combination of heat with DOX (5.0 mg/kg, i.v.) enhanced tumour growth delay. The combined therapy, however, showed increased toxicity to normal tissue (especially renal and cardiac). Although DOX levels in spleen tissue were higher in rats exposed to hyperthermia than in control normothermic rats, both groups had comparable levels of drug in tumour, heart, kidney, and small intestine tissue at all time-points examined. Compared with normothermic animals, hyperthermia-treated rats showed decreased DOX in the mean area under the concentration-time curve (AUC) and decreased plasma DOX t1/2 but increased plasma drug clearance. These heat-mediated alterations in DOX pharmacokinetic parameters, however, do not account for the significant increases in thermochemotherapy-mediated cytotoxicities observed in tumour, and in normal renal and cardiac tissues.

Report this publication

Statistics

Seen <100 times